Please assess the completion status of the following clinical trial:

Trial Title: Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants who are classically healthy having no clinically relevant abnormalities. No known or suspected hepatic impairment~* Stable hepatic impairment that meets the criteria for Class B of the Child-Pugh Classification~Exclusion Criteria:~* Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).~* Participants who have been vaccinated with COVID-19 vaccines within the past week of dosing~* A positive urine drug test, for illicit drugs, at Screening~* History of sensitivity reactions to ritonavir or any of the formulation components of PF-07321332 or ritonavir.~* eGFR \<60 mL/min/1.73m2 based on the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥ upper limit of normal (ULN) (for healthy participants); AST or ALT \> 5x ULN (for hepatic impairment participants)~* Albumin \> ULN (for healthy participants);~* Prothrombin time \> ULN (for healthy participants);~* Total bilirubin level ≥1.5 × ULN \[NOTE: Participants with a history of Gilbert syndrome (and hence elevated total bilirubin) are eligible provided direct bilirubin level is ≤ ULN).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Healthy Volunteer
- Cohort 2 (Type: EXPERIMENTAL): Hepatic Impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).